AHEAD
Start date:Historic End date:
March 2013 Co-ordinated by:
University of Sheffield
Monitoring anticoagulated patients who suffer head injury
Aim
- Identify the outcomes of anticoagulated patients attending the ED following head injury
- Collect prospective data to enable the risk of serious intracranial pathology to be calculated for this patient group (defined in this study as death or neurosurgery resulting from the initial injury, or Computerised Tomography (CT) scan finding mandating admission or readmission to hospital)
- Use baseline and follow up data to identify useful predictors of adverse outcome in this patient group
- Evaluate the cost-effectiveness of different clinical management strategies for this patient group
- Identify important factors in the clinical consultation and assessment process following head injury that may be useful as a diagnostic tool.
Trial Design
Prospective, multi-centre, pragmatic observational cohort study
Chief Investigator
Professor Suzanne Mason
Local PI
Dr. Matt Reed
List of Publications – references
Mason S, Kuczawski M, Teare M, Stevenson M, Holmes M, Ramlakhan S, Goodacr S, Morris F, Harper R: THE AHEAD STUDY: MANAGING ANTICOAGULATED PATIENTS WHO SUFFER HEAD INJURY. Emergency Medicine Journal (2014);31:775
Local PI
Dr Matt Reed
Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine
More EMERGE Trials
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.